Ursodeoxycholic Acid in Patients With Chronic Heart Failure

Ursodeoxycholic Acid in Patients With Chronic Heart Failure

Objectives This study sought to assess the effects of ursodeoxycholic acid (UDCA) on endothelial function and inflammatory markers in patients with chronic heart failure (CHF). Background Endothelial dysfunction is commonly observed in patients with CHF, and it contributes to the limitation in exerc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2012-02, Vol.59 (6), p.585-592
Hauptverfasser: von Haehling, Stephan, MD, PhD, Schefold, Joerg C., MD, Jankowska, Ewa A., MD, PhD, Springer, Jochen, PhD, Vazir, Ali, MBBS, PhD, Kalra, Paul R., MD, Sandek, Anja, MD, Fauler, Günter, PhD, Stojakovic, Tatjana, MD, Trauner, Michael, MD, Ponikowski, Piotr, MD, PhD, Volk, Hans-Dieter, MD, Doehner, Wolfram, MD, PhD, Coats, Andrew J.S., DM, Poole-Wilson, Philip A., MD, Anker, Stefan D., MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Acids
blood flow
Blood pressure
Cardiology
Cardiovascular
Cardiovascular disease
Cytokines
Drug therapy
Enzymes
Heart attacks
Heart failure
Heart rate
inflammation
Internal Medicine
Laboratories
Morphology
Patients
ursodeoxycholic acid
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives This study sought to assess the effects of ursodeoxycholic acid (UDCA) on endothelial function and inflammatory markers in patients with chronic heart failure (CHF). Background Endothelial dysfunction is commonly observed in patients with CHF, and it contributes to the limitation in exercise capacity that accompanies this condition. Bacterial lipopolysaccharide may trigger proinflammatory cytokine release and promote further endothelial dysfunction. UDCA, a bile acid used in the treatment of cholestatic liver disease, has anti-inflammatory and cytoprotective properties and may contribute to the formation of mixed micelles around lipopolysaccharide. These properties may help to improve peripheral blood flow in patients with CHF. Methods We performed a prospective, single-center, double-blind, randomized, placebo-controlled crossover study of UDCA in 17 clinically stable male patients with CHF (New York Heart Association functional class II/III, left ventricular ejection fraction
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2011.10.880